Samsara BioCapital LLC Has $242.59 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

Samsara BioCapital LLC trimmed its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 17.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,612,896 shares of the company's stock after selling 1,175,713 shares during the period. Scholar Rock makes up 32.9% of Samsara BioCapital LLC's investment portfolio, making the stock its largest holding. Samsara BioCapital LLC owned 6.00% of Scholar Rock worth $242,589,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after buying an additional 3,439,215 shares during the period. Marshall Wace LLP lifted its holdings in Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after acquiring an additional 2,732,546 shares during the period. Norges Bank purchased a new position in Scholar Rock in the fourth quarter worth about $86,043,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Scholar Rock during the 4th quarter valued at about $68,930,000. Finally, Wellington Management Group LLP increased its position in shares of Scholar Rock by 763.8% during the 4th quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company's stock valued at $74,581,000 after purchasing an additional 1,525,845 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Stock Performance

Shares of SRRK stock traded up $0.15 during trading hours on Friday, reaching $32.91. 1,339,190 shares of the company traded hands, compared to its average volume of 1,258,817. The firm has a 50-day moving average price of $32.26 and a 200 day moving average price of $35.78. The company has a market cap of $3.12 billion, a P/E ratio of -14.00 and a beta of 0.56. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98.

Insiders Place Their Bets

In other Scholar Rock news, insider Tracey Sacco sold 5,000 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total transaction of $164,150.00. Following the sale, the insider now directly owns 71,750 shares of the company's stock, valued at $2,355,552.50. This trade represents a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mo Qatanani sold 68,510 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the transaction, the insider now owns 111,084 shares in the company, valued at $4,154,541.60. The trade was a 38.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 255,231 shares of company stock worth $9,220,236. Company insiders own 13.30% of the company's stock.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.